A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply